Literature DB >> 32414099

Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.

Melissa Davis1, Rachel Martini1, Lisa Newman1, Olivier Elemento2,3,4, Jason White5, Akanksha Verma6, Indrani Datta7, Indra Adrianto7, Yalei Chen7, Kevin Gardner8, Hyung-Gyoon Kim9, Windy D Colomb5,10, Isam-Eldin Eltoum9,11, Andra R Frost9,11, William E Grizzle9,11,12, Andrea Sboner3,4,13, Upender Manne9,11, Clayton Yates5.   

Abstract

Triple negative breast cancers (TNBCs) are molecularly heterogeneous, and the link between their aggressiveness with African ancestry is not established. We investigated primary TNBCs for gene expression among self-reported race (SRR) groups of African American (AA, n = 42) and European American (EA, n = 33) women. RNA sequencing data were analyzed to measure changes in genome-wide expression, and we utilized logistic regressions to identify ancestry-associated gene expression signatures. Using SNVs identified from our RNA sequencing data, global ancestry was estimated. We identified 156 African ancestry-associated genes and found that, compared to SRR, quantitative genetic analysis was a more robust method to identify racial/ethnic-specific genes that were differentially expressed. A subset of African ancestry-specific genes that were upregulated in TNBCs of our AA patients were validated in TCGA data. In AA patients, there was a higher incidence of basal-like two tumors and altered TP53, NFB1, and AKT pathways. The distinct distribution of TNBC subtypes and altered oncologic pathways show that the ethnic variations in TNBCs are driven by shared genetic ancestry. Thus, to appreciate the molecular diversity of TNBCs, tumors from patients of various ancestral origins should be evaluated.

Entities:  

Keywords:  African ancestry; RNAseq analysis; disparities; oncologic pathways; triple negative breast cancer

Year:  2020        PMID: 32414099     DOI: 10.3390/cancers12051220

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

Review 1.  Breast cancer disparities in outcomes; unmasking biological determinants associated with racial and genetic diversity.

Authors:  Rachel Martini; Lisa Newman; Melissa Davis
Journal:  Clin Exp Metastasis       Date:  2021-05-05       Impact factor: 4.510

2.  Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survival.

Authors:  Sandeep K Singhal; Jung S Byun; Samson Park; Tingfen Yan; Ryan Yancey; Ambar Caban; Sara Gil Hernandez; Stephen M Hewitt; Heike Boisvert; Stephanie Hennek; Mark Bobrow; Md Shakir Uddin Ahmed; Jason White; Clayton Yates; Andrew Aukerman; Rami Vanguri; Rohan Bareja; Romina Lenci; Paula Lucia Farré; Adriana De Siervi; Anna María Nápoles; Nasreen Vohra; Kevin Gardner
Journal:  Commun Biol       Date:  2021-02-01

3.  Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression.

Authors:  Sumit Siddharth; Sheetal Parida; Nethaji Muniraj; Shawn Hercules; David Lim; Arumugam Nagalingam; Chenguang Wang; Balazs Gyorffy; Juliet M Daniel; Dipali Sharma
Journal:  Elife       Date:  2021-12-10       Impact factor: 8.140

4.  Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer.

Authors:  Shawn M Hercules; Xiyu Liu; Blessing B I Bassey-Archibong; Desiree H A Skeete; Suzanne Smith Connell; Adetola Daramola; Adekunbiola A Banjo; Godwin Ebughe; Thomas Agan; Ima-Obong Ekanem; Joe Udosen; Christopher Obiorah; Aaron C Ojule; Michael A Misauno; Ayuba M Dauda; Ejike C Egbujo; Jevon C Hercules; Amna Ansari; Ian Brain; Christine MacColl; Yili Xu; Yuxin Jin; Sharon Chang; John D Carpten; André Bédard; Greg R Pond; Kim R M Blenman; Zarko Manojlovic; Juliet M Daniel
Journal:  Cancer Causes Control       Date:  2022-04-06       Impact factor: 2.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.